COVID-19 in Lung Transplant Recipients: A Report on 10 Recent Cases
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Koczulla, R.A.; Sczepanski, B.; Koteczki, A.; Kuhnert, S.; Hecker, M.; Askevold, I.; Schneider, C.; Michel, S.; Kneidinger, N. SARS-CoV-2 infection in two patients following recent lung transplantation. Am. J. Transplant. 2020, 20, 2928–2932. [Google Scholar] [CrossRef]
- DeWolf, S.; Laracy, J.C.; Perales, M.-A.; Kamboj, M.; van den Brink, M.R.M.; Vardhana, S. SARS-CoV-2 in immunocompromised individuals. Immunity 2022, 55, 1779–1798. [Google Scholar] [CrossRef]
- Rydyznski Moderbacher, C.; Ramirez, S.I.; Dan, J.M.; Grifoni, A.; Hastie, K.M.; Weiskopf, D.; Belanger, S.; Abbott, R.K.; Kim, C.; Choi, J.; et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell 2020, 183, 996–1012.e1019. [Google Scholar] [CrossRef]
- Bange, E.M.; Han, N.A.; Wileyto, P.; Kim, J.Y.; Gouma, S.; Robinson, J.; Greenplate, A.R.; Hwee, M.A.; Porterfield, F.; Owoyemi, O.; et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat. Med. 2021, 27, 1280–1289. [Google Scholar] [CrossRef]
- Dispinseri, S.; Secchi, M.; Pirillo, M.F.; Tolazzi, M.; Borghi, M.; Brigatti, C.; De Angelis, M.L.; Baratella, M.; Bazzigaluppi, E.; Venturi, G.; et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat. Commun. 2021, 12, 2670. [Google Scholar] [CrossRef]
- Hueso, T.; Pouderoux, C.; Péré, H.; Beaumont, A.L.; Raillon, L.A.; Ader, F.; Chatenoud, L.; Eshagh, D.; Szwebel, T.A.; Martinot, M.; et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood 2020, 136, 2290–2295. [Google Scholar] [CrossRef]
- Purpura, L.J.; Chang, M.; Annavajhala, M.K.; Mohri, H.; Liu, L.; Shah, J.; Cantos, A.; Medrano, N.; Laracy, J.; Scully, B.; et al. Prolonged severe acute respiratory syndrome coronavirus 2 persistence, attenuated immunologic response, and viral evolution in a solid organ transplant patient. Am. J. Transplant. 2022, 22, 649–653. [Google Scholar] [CrossRef]
- Wang, Z.; Schmidt, F.; Weisblum, Y.; Muecksch, F.; Barnes, C.O.; Finkin, S.; Schaefer-Babajew, D.; Cipolla, M.; Gaebler, C.; Lieberman, J.A.; et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 2021, 592, 616–622. [Google Scholar] [CrossRef]
- Guerrera, G.; Picozza, M.; D’Orso, S.; Placido, R.; Pirronello, M.; Verdiani, A.; Termine, A.; Fabrizio, C.; Giannessi, F.; Sambucci, M.; et al. The BNT162b2 mRNA vaccine induces polyfunctional T cell responses with features of longevity. bioRxiv 2021. [Google Scholar] [CrossRef]
- Meshram, H.S.; Kute, V.; Rane, H.; Dave, R.; Banerjee, S.; Mishra, V.; Chauhan, S. Humoral and cellular response of COVID-19 vaccine among solid organ transplant recipients: A systematic review and meta-analysis. Transpl. Infect. Dis. 2022, 24, e13926. [Google Scholar] [CrossRef]
- Mair, M.J.; Mitterer, M.; Gattinger, P.; Berger, J.M.; Trutschnig, W.; Bathke, A.C.; Gansterer, M.; Berghoff, A.S.; Laengle, S.; Gottmann, L.; et al. Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron. Cancer Cell 2022, 40, 444–446. [Google Scholar] [CrossRef]
- Harrington, P.; Doores, K.J.; Saha, C.; Saunders, J.; Child, F.; Dillon, R.; Saglam, S.; Raj, K.; McLornan, D.; Avenoso, D.; et al. Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients. Cancer Cell 2021, 39, 1448–1449. [Google Scholar] [CrossRef]
- Brown, L.K.; Moran, E.; Goodman, A.; Baxendale, H.; Bermingham, W.; Buckland, M.; AbdulKhaliq, I.; Jarvis, H.; Hunter, M.; Karanam, S.; et al. Treatment of chronic or relapsing COVID-19 in immunodeficiency. J. Allergy Clin. Immunol. 2022, 149, 557–561.e551. [Google Scholar] [CrossRef]
- Destras, G.; Bal, A.; Simon, B.; Lina, B.; Josset, L. Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients. Lancet Microbe 2022, 3, e559. [Google Scholar] [CrossRef]
- Jee, J.; Foote, M.B.; Lumish, M.; Stonestrom, A.J.; Wills, B.; Narendra, V.; Avutu, V.; Murciano-Goroff, Y.R.; Chan, J.E.; Derkach, A.; et al. Chemotherapy and COVID-19 Outcomes in Patients with Cancer. J. Clin. Oncol. 2020, 38, 3538–3546. [Google Scholar] [CrossRef]
- Robilotti, E.V.; Babady, N.E.; Mead, P.A.; Rolling, T.; Perez-Johnston, R.; Bernardes, M.; Bogler, Y.; Caldararo, M.; Figueroa, C.J.; Glickman, M.S.; et al. Determinants of COVID-19 disease severity in patients with cancer. Nat. Med. 2020, 26, 1218–1223. [Google Scholar] [CrossRef]
- An, W.; Wang, Q.; Kim, T.E.; Kang, J.S. Clinical characteristics and outcome of coronavirus disease 2019 infection in patients with solid organ transplants: A systematic review and meta-analysis. J. Infect. Public Health 2022, 15, 365–372. [Google Scholar] [CrossRef]
- Gatti, M.; Rinaldi, M.; Bussini, L.; Bonazzetti, C.; Pascale, R.; Pasquini, Z.; Faní, F.; Pinho Guedes, M.N.; Azzini, A.M.; Carrara, E.; et al. Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: A systematic review and meta-analysis. Clin. Microbiol. Infect. 2022, 28, 1057–1065. [Google Scholar] [CrossRef]
- Saez-Giménez, B.; Berastegui, C.; Barrecheguren, M.; Revilla-López, E.; Los Arcos, I.; Alonso, R.; Aguilar, M.; Mora, V.M.; Otero, I.; Reig, J.P.; et al. COVID-19 in lung transplant recipients: A multicenter study. Am. J. Transplant. 2021, 21, 1816–1824. [Google Scholar] [CrossRef]
- Trindade, A.J.; Chapin, K.C.; Gannon, W.D.; Hoy, H.; Demarest, C.T.; Lambright, E.S.; McPherson, K.A.; Norfolk, S.G.; Robbins, I.M.; Bacchetta, M.; et al. Clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients. Transpl. Infect. Dis. 2022, 24, e13967. [Google Scholar] [CrossRef]
- Mahan, L.D.; Lill, I.; Halverson, Q.; Mohanka, M.R.; Lawrence, A.; Joerns, J.; Bollineni, S.; Kaza, V.; La Hoz, R.M.; Zhang, S.; et al. Post-infection pulmonary sequelae after COVID-19 among patients with lung transplantation. Transpl. Infect. Dis. 2021, 23, e13739. [Google Scholar] [CrossRef]
- Messika, J.; Eloy, P.; Roux, A.; Hirschi, S.; Nieves, A.; Le Pavec, J.; Sénéchal, A.; Saint Raymond, C.; Carlier, N.; Demant, X.; et al. COVID-19 in Lung Transplant Recipients. Transplantation 2021, 105, 177–186. [Google Scholar] [CrossRef]
- Kamp, J.C.; Hinrichs, J.B.; Fuge, J.; Ewen, R.; Gottlieb, J. COVID-19 in lung transplant recipients-Risk prediction and outcomes. PLoS ONE 2021, 16, e0257807. [Google Scholar] [CrossRef]
- Heldman, M.R.; Kates, O.S.; Safa, K.; Kotton, C.N.; Georgia, S.J.; Steinbrink, J.M.; Alexander, B.D.; Hemmersbach-Miller, M.; Blumberg, E.A.; Crespo, M.M.; et al. COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: A comparative analysis from a multicenter study. Am. J. Transplant. 2021, 21, 2774–2784. [Google Scholar] [CrossRef]
- Kneidinger, N.; Hecker, M.; Bessa, V.; Hettich, I.; Wald, A.; Wege, S.; Nolde, A.B.; Oldigs, M.; Syunyaeva, Z.; Wilkens, H.; et al. Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: A Nationwide German study. Infection 2023, 51, 749–757. [Google Scholar] [CrossRef]
- Shostak, Y.; Kramer, M.R.; Edni, O.; Glusman Bendersky, A.; Shafran, N.; Bakal, I.; Heching, M.; Rosengarten, D.; Shitenberg, D.; Amor, S.M.; et al. Immunogenicity of a Third Dose of BNT162b2 Vaccine among Lung Transplant Recipients—A Prospective Cohort Study. Vaccines 2023, 11, 799. [Google Scholar] [CrossRef]
- Mitchell, J.; Alejo, J.L.; Chiang, T.P.Y.; Kim, J.; Chang, A.; Abedon, A.T.; Avery, R.K.; Tobian, A.A.R.; Massie, A.B.; Levan, M.L.; et al. Antibody Response to a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: An Update. Transplantation 2022, 106, e338–e340. [Google Scholar] [CrossRef]
- Scharringa, S.; Hoffman, T.; van Kessel, D.A.; Rijkers, G.T. Vaccination and their importance for lung transplant recipients in a COVID-19 world. Expert. Rev. Clin. Pharmacol. 2021, 14, 1413–1425. [Google Scholar] [CrossRef]
- Núñez-Orantos, M.J.; Julián-Jiménez, A.; Candel, F.J.; González Del Castillo, J. Therapeutic strategy in the transplanted patient. Rev. Esp. Quimioter. 2023, 36 (Suppl. S1), 18–21. [Google Scholar] [CrossRef]
- Gottlieb, J.; Simon, S.; Barton, J.; Barnikel, M.; Bachmann, M.; Klingenberg, M.S.; Veit, T.; Kneidinger, N. Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: A two center cohort study during the omicron era. Infection 2023, 51, 1481–1489. [Google Scholar] [CrossRef]
Prior Immune Status | Clinical Symptoms | Remdesivir? | Prolonged Infection > 14 d? |
---|---|---|---|
Combined heart-lung-Tx 1998 due to primary pulmonary hypertension, 34 y. old | |||
4× vaccination, 1× infection | Mild symptoms of a cold | No | No |
Bilateral LTX 9/2023 due to pulmonary fibrosis, 58 y. old | |||
3× vaccination, 1× infection | No symptoms | Yes, start appr. 5 days after positive test | Yes |
Bilateral LTX 8/2023 due to lymphangioleiomyomatosis, 49 y. old | |||
4× vaccination | Mild fatigue | Yes, start approx. 1 day after positive test, treatment for 10 days | Yes |
Bilateral LTX 10/2023 due to interstitial lung disease with systemic sclerosis, 54 y. old | |||
4× vaccination, 1× infection | Mild symptoms of a cold | Yes, start approx. 5 days after onset of symptoms | No |
Bilateral LTX 10/2023 due to chronic obstructive pulmonary disease, 60 y. old | |||
3× vaccination | No symptoms | No | No |
Bilateral LTX 08/2023 due to pulmonary fibrosis, 54 y. old | |||
2× vaccination, 1× infection | No symptoms | No | No |
Bilateral LTX 10/2023 due to interstitial lung disease with amyloidosis, 59 y. old | |||
3× vaccination, 1× infection | Fatigue, limb pain, sore throat, cough | Yes, start 1 day after onset of symptoms | No |
Bilateral LTX 2023 *1 due to chronic obstructive pulmonary disease, 63 y. old | |||
3× vaccination, 1× infection | Cough, fever, vomiting *2 | Yes, start 4 days after positive test | No |
Bilateral LTX 12/2023 due to non-CF bronchiectasis, 35 y. old | |||
4× vaccination, 2× infection | Fatigue, chills | Yes, start 4 days after positive test | Yes |
Right-side single-LTX 11/2023 due to pulmonary fibrosis, 67 y. old | |||
5× vaccination | No symptoms | Yes, start approx. 4 days after onset of symptoms | No |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Reemann, L.; Kneidinger, N.; Sczepanski, B.; Koczulla, A.R. COVID-19 in Lung Transplant Recipients: A Report on 10 Recent Cases. Viruses 2024, 16, 709. https://doi.org/10.3390/v16050709
Reemann L, Kneidinger N, Sczepanski B, Koczulla AR. COVID-19 in Lung Transplant Recipients: A Report on 10 Recent Cases. Viruses. 2024; 16(5):709. https://doi.org/10.3390/v16050709
Chicago/Turabian StyleReemann, Lea, Nikolaus Kneidinger, Bernd Sczepanski, and Andreas Rembert Koczulla. 2024. "COVID-19 in Lung Transplant Recipients: A Report on 10 Recent Cases" Viruses 16, no. 5: 709. https://doi.org/10.3390/v16050709
APA StyleReemann, L., Kneidinger, N., Sczepanski, B., & Koczulla, A. R. (2024). COVID-19 in Lung Transplant Recipients: A Report on 10 Recent Cases. Viruses, 16(5), 709. https://doi.org/10.3390/v16050709